IMMU-132-13: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

Condition: | Last Updated: 4 Apr 21 | Status: enrolling

View Full Study